Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F21%3AN0000134" target="_blank" >RIV/00064190:_____/21:N0000134 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/21:10421083

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1111/all.14295" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/all.14295</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.14295" target="_blank" >10.1111/all.14295</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Popis výsledku v původním jazyce

Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to asthma, allergies, and allied diseases. Prostaglandins and leukotrienes are the most studied eicosanoids and established inducers of airway pathophysiology including bronchoconstriction and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently prostaglandin D-2 receptor antagonists, have been shown to modulate features of asthma and allergic diseases. This review, produced by an European Academy of Allergy and Clinical Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology and its role in mediating human pathology, with a focus on new findings relevant for clinical practice, development of novel therapeutics, and future research opportunities.

Název v anglickém jazyce

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Popis výsledku anglicky

Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to asthma, allergies, and allied diseases. Prostaglandins and leukotrienes are the most studied eicosanoids and established inducers of airway pathophysiology including bronchoconstriction and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently prostaglandin D-2 receptor antagonists, have been shown to modulate features of asthma and allergic diseases. This review, produced by an European Academy of Allergy and Clinical Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology and its role in mediating human pathology, with a focus on new findings relevant for clinical practice, development of novel therapeutics, and future research opportunities.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30225 - Allergy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ALLERGY

ISSN

0105-4538

e-ISSN

1398-9995

Svazek periodika

76

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

114-130

Kód UT WoS článku

000605369400007

EID výsledku v databázi Scopus

2-s2.0-85089338536